Figure 8.

Induction of complete elimination of low-grade tumour under multimodal therapy, inversely reconstructed with bias shift: astrocytoma III. (A) Tumour cell population as therapy progresses, the population becomes zero at point P, after 40.11 days, the system is tracked for 800 days in the inset figure, to confirm the full extinction of tumour cells without any relapse over a period of 800 days. (B) The temporal variation of the Cytotoxic CD8+ lymphocyte population needed for full regression of tumour. One discerns the bimodal temporal dose-profile with two peaks at A and B. (C) The temporal profile of Temozolomide concentration necessary for tumour elimination. There is evidently an unimodal temporal dose-profile with the hump D, thence the chemotherapy level diminishes to point E; (D) The level of Interleukin-2 concentration required for extinction of the tumour cells. One notes the substantial level of interleukin (F), with truncation so as to have the level below the toxicity limit of interleukin in Table 2. (E) Natural killer cell population, N that does not cross the upper bound of physiological limits (Table 2). (F) Circulating lymphocyte population, C that can also be maintained below the upper bound of physiological limits (Table 2). (G) Injected daily dose-rate of Tumour-infiltrating Lymphocyte which is necessary for tumour elimination. An elevated pulse dosage injection essential at the latter part of the therapy, is delineated by arrow. (H) Injected daily dose-rate of Temozolomide chemotherapy that is requisite for the tumour regression. The pulse dosage injection required at the latter duration of the therapy, is shown by an arrow. (I) Injected daily dose-rate of Interleukin-2 that is needed for the extinction of tumour cells. An arrow shows the pulse dosage injection (point G) needed at the terminal portion of the therapy.